Jaguar Gene Therapy, a biotechnology firm based in Illinois, has been making significant strides in the development of gene therapies for severe genetic diseases, with a particular focus on conditions that affect large patient populations. Three years after its emergence from stealth mode, backed by Deerfield Management, the company has made headlines with the establishment of Advanced Medicine Partners. This spinout, supported by Deerfield, ARCH Venture Partners, and Nolan Capital, takes over the chemistry, manufacturing, and controls (CMC) responsibilities previously held by Jaguar. Advanced Medicine Partners aims to excel in the development of advanced medicines, including gene and cell therapies, by addressing the challenges of quality and scalability that have previously hampered the introduction of new treatments.
The collaboration between Jaguar Gene Therapy and Advanced Medicine Partners is a testament to their shared commitment to advancing healthcare. Advanced Medicine Partners, besides undertaking contract work, will spearhead the CMC efforts for Jaguar’s ongoing projects. These projects include promising treatments for genetic disorders like autism, Type 1 diabetes, and Type 1 galactosemia. To support these endeavors, Advanced Medicine Partners is constructing a 174,000-square-foot manufacturing facility in Durham, North Carolina. This facility is designed to augment their capacity for partner projects and is a direct result of Jaguar’s significant investment, following closely after their Series A and B funding rounds.
In a recent breakthrough, Jaguar Gene Therapy announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for JAG201. This gene therapy targets a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS), conditions for which there are currently no treatments available. JAG201 aims to deliver a functional SHANK3 gene directly into the central nervous system using the AAV9 vector, addressing the root cause of the disease. Preclinical studies have shown promising results, demonstrating improvements in neurobehavioral, cognitive, and motor functions. The company is planning to initiate Phase I clinical trials in the latter half of the year, marking a significant step forward in the treatment of these disorders.
The efforts of Jaguar Gene Therapy and its partners reflect a broader commitment to addressing unmet medical needs within the field of genetic disorders. The work on JAG201, in particular, offers hope to the approximately 30,000 individuals in the U.S. suffering from ASD or PMS related to SHANK3 mutations or deletions. Through collaborations with esteemed institutions and leveraging cutting-edge science, Jaguar Gene Therapy is poised to potentially transform the lives of patients and their families, offering them treatments that target the underlying causes of their conditions. As the company moves forward with its clinical trials, it stands on the forefront of a new era in gene therapy, bringing us closer to realizing the full potential of these groundbreaking treatments.
1. https://www.biospace.com/article/releases/jaguar-gene-therapy-announces-fda-clearance-of-ind-to-study-jag201-in-a-genetic-form-of-autism-spectrum-disorder-and-phelan-mcdermid-syndrome/
2. https://www.fiercepharma.com/manufacturing/fda-slams-eugia-form-483-posts-reprimands-agc-baxter-last-year
3. https://jaguargenetherapy.com/press-release/jaguar-gene-therapy-announces-fda-clearance-of-ind-to-study-jag201-in-a-genetic-form-of-autism-spectrum-disorder-and-phelan-mcdermid-syndrome/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
